Evaluating The Effectiveness of Hepatitis B Pmtct Interventions: A Comparative Analysis of Models of Care in Sardauna and Kurmi Lgas, Taraba State, Nigeria

Authors

Danjuma Adda

Center for Initiative and Development (CFID) Taraba (Nigeria)

Daniel Lawrence

Center for Initiative and Development (CFID) Taraba (Nigeria)

Obed Tiwah John

Center for Initiative and Development (CFID) Taraba (Nigeria)

Rijimra Ande

Center for Initiative and Development (CFID) Taraba (Nigeria)

Helmina Bantar

Center for Initiative and Development (CFID) Taraba (Nigeria)

Edward Yibon Stephen

Center for Initiative and Development (CFID) Taraba (Nigeria)

Tomen E Agu

Department of Public Health, Taraba State University, Jalingo (Nigeria)

Mohammed Umaru

Center for Initiative and Development (CFID) Taraba (Nigeria)

Emmanuel Nicodemus

Center for Initiative and Development (CFID) Taraba (Nigeria)

Article Information

DOI: 10.51244/IJRSI.2025.1215PH000205

Subject Category: Public Health

Volume/Issue: 12/15 | Page No: 2704-2711

Publication Timeline

Submitted: 2025-11-10

Accepted: 2025-11-20

Published: 2025-12-05

Abstract

Background:
Hepatitis B virus (HBV) remains a major public health concern in Nigeria, where mother-to-child transmission (MTCT) contributes significantly to chronic infections. This study evaluated the effectiveness of HBV PMTCT interventions implemented in Sardauna LGA (2023) and Kurmi LGA (2024) in Taraba State, comparing screening coverage, prophylaxis uptake, and childhood immunization outcomes across the two models of care.
Methods:
A descriptive analysis was conducted using programme data from both LGAs, encompassing HBV/HCV screening among pregnant women, women of childbearing age (CBA), and male partners; initiation of Tenofovir prophylaxis for HBV-positive pregnant women; and uptake of HBV birth-dose and subsequent childhood vaccinations. Health worker capacity-building outputs and step-down training outcomes were also assessed.
Results:
In Sardauna LGA, 2,426 individuals were screened, identifying 99 HBsAg-positive and 34 Anti-HCV-positive cases; all 56 HBV-positive pregnant women received Tenofovir prophylaxis. Similarly, Kurmi LGA screened 1,435 individuals, identifying 101 HBsAg-positive and 65 Anti-HCV-positive cases, with full prophylaxis initiation for all 58 HBV-positive pregnant women. Birth-dose vaccination within 24 hours was high in both LGAs—1,357 infants in Sardauna and 850 in Kurmi—although attrition across the vaccine series persisted, with only 1,005 and 484 infants completing the pentavalent schedule, respectively. Screening indicators fell short of five-year EMTCT targets, whereas infant vaccination and health workforce training exceeded expectations. Step-down training improved health worker knowledge, service readiness, antenatal care uptake, HBV screening rates, and birth-dose vaccination performance.
Conclusion: The HBV PMTCT interventions demonstrated strong maternal prophylaxis coverage, improved service availability, and high birth-dose uptake across both LGAs. However, screening coverage for pregnant women, women of CBA, and male partners remained below targets, and vaccine completion rates showed notable drop-offs. Strengthening community outreach, improving facility-based deliveries, and enhancing follow-up systems are critical to achieving HBV EMTCT goals in Taraba State.

Keywords

Hepatitis B, PMTCT, Tenofovir prophylaxis, birth-dose vaccination

Downloads

References

1. Musa, B. M., Bussell, S., Borodo, M. M., Samaila, A. A., & Femi, O. L. (2015). Prevalence of hepatitis B virus infection in Nigeria, 2000–2013: a systematic review and meta-analysis. Nigerian Journal of Clinical Practice, 18(2), 163–172. [Google Scholar] [Crossref]

2. WHO (2020). Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. World Health Organization. [Google Scholar] [Crossref]

3. Adjei, C. A., Asamoah, R., Atibilla, D., Owusu-Agyei, S., & Ameme, D. K. (2021). Uptake of birth dose hepatitis B vaccine in rural Ghana: Challenges and strategies. BMC Public Health, 21(1), 1-10. [Google Scholar] [Crossref]

4. Nelson, N. P., Easterbrook, P. J., & McMahon, B. J. (2023). Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clinical Liver Disease, 19(1), 1-14. [Google Scholar] [Crossref]

5. Eke, A. C., Eleje, G. U., Eke, U. A., Xia, Y., & Liu, J. (2019). Hepatitis B immunization in pregnancy: Effect of knowledge and attitude of antenatal women in Nigeria. BMC Public Health, 19(1), 1-9. [Google Scholar] [Crossref]

6. Olayinka, A. T., Oyemakinde, A., Balogun, M. S., Ajudua, A., Nguku, P., Aderinola, M., ... & Nasidi, A. (2016). Seroprevalence of hepatitis B infection in Nigeria: A national survey. The American Journal of Tropical Medicine and Hygiene, 95(4), 902–907. [Google Scholar] [Crossref]

7. Federal Ministry of Health, Nigeria (2016). National Guidelines for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. [Google Scholar] [Crossref]

8. CFID. (2021). Report on hepatitis B and C prevalence in Taraba State. www.cfidtaraba.org [Google Scholar] [Crossref]

9. Federal Ministry of Health (FMoH). (2018). National Hepatitis B and C control guidelines. [Google Scholar] [Crossref]

10. Hyun, M. H., et al. (2020). "Impact of early HBV vaccination on the prevention of vertical transmission." Vaccine, 38(3), 465-471. [Google Scholar] [Crossref]

11. Kabore HJ, Li X, Alleman MM, et al. Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — World Health Organization African Region, 2016–2021. MMWR Morb Mortal Wkly Rep 2023;72:782–787. DOI: http://dx.doi.org/10.15585/mmwr.mm7229a2 [Google Scholar] [Crossref]

12. Kabore, H. A., et al. (2023). Viral hepatitis elimination goals. The Lancet. [Google Scholar] [Crossref]

13. NAIIS. (2018). Nigerian AIDS Indicator and Impact Survey: Technical Report. [Google Scholar] [Crossref]

14. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva: World Health Organization 2020 PubMed/NCBI [Google Scholar] [Crossref]

15. Sintusek P, Wanlapakorn N, Poovorawan Y. Strategies to Prevent Mother-to-child Transmission of Hepatitis B Virus. J Clin Transl Hepatol. 2023;11(4):967-974. doi: 10.14218/JCTH.2023.00332. [Google Scholar] [Crossref]

16. WHO. (2020). Elimination of mother-to-child transmission of hepatitis B. World Health Organization. [Google Scholar] [Crossref]

17. WHO. (2023). Global hepatitis report. World Health Organization. [Google Scholar] [Crossref]

18. World Health Organization (WHO). (2021). "Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis." Geneva: World Health Organization. [Google Scholar] [Crossref]

19. Xu, Y., et al. (2019). "Tenofovir prophylaxis for preventing perinatal transmission of hepatitis B virus infection." Journal of Clinical Virology, 112, 15-20. [Google Scholar] [Crossref]

Metrics

Views & Downloads

Similar Articles